Evinacumab in Patients with Refractory Hypercholesterolemia
Angiopoietin-like 3 is an inhibitor of lipoprotein lipase. Evinacumab is a monoclonal antibody that inhibits angiopoietin-like 3, activating lipoprotein lipase. In patients with hypercholesterolemia that is refractory to statin and PCSK9 inhibitor therapy, the use of evinacumab reduced plasma lipid...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2020-12, Vol.383 (24), p.2307-2319 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2319 |
|---|---|
| container_issue | 24 |
| container_start_page | 2307 |
| container_title | The New England journal of medicine |
| container_volume | 383 |
| creator | Rosenson, Robert S Burgess, Lesley J Ebenbichler, Christoph F Baum, Seth J Stroes, Erik S.G Ali, Shazia Khilla, Nagwa Hamlin, Robert Pordy, Robert Dong, Yuping Son, Vladimir Gaudet, Daniel |
| description | Angiopoietin-like 3 is an inhibitor of lipoprotein lipase. Evinacumab is a monoclonal antibody that inhibits angiopoietin-like 3, activating lipoprotein lipase. In patients with hypercholesterolemia that is refractory to statin and PCSK9 inhibitor therapy, the use of evinacumab reduced plasma lipid levels by more than 50% at the maximum dose. |
| doi_str_mv | 10.1056/NEJMoa2031049 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2468693508</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2468693508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-3cbb89937697ded5b4c91a492e6c21f1c73b17b9874611f8b00bcec671a853bf3</originalsourceid><addsrcrecordid>eNp10E1LAzEQBuAgiq3Vo1dZEI-rmU02H3iSUq1SPxA9hyTN0i3Nbk12lf57I1XBg3OZy8M7w4vQMeBzwCW7eJjc3be6wAQwlTtoCCUhOaWY7aIhxoXIKZdkgA5iXOI0QOU-GhACkiU5RJeT97rRtvfaZHWTPemudk0Xs4-6W2TPrgradm3YZNPN2gW7aFcudi6k5Wt9iPYqvYru6HuP0Ov15GU8zWePN7fjq1luicRdTqwxQkrCmeRzNy8NtRI0lYVjtoAKLCcGuJGCUwZQCYOxsc4yDlqUxFRkhE63uevQvvXpAbVs-9Ckk6qgTDBJSiySyrfKhjbG4Cq1DrXXYaMAq6-q1J-qkj_5Tu2Nd_Nf_dNNAmdb4H1UjVv6f4I-AdDobu0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2468693508</pqid></control><display><type>article</type><title>Evinacumab in Patients with Refractory Hypercholesterolemia</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Rosenson, Robert S ; Burgess, Lesley J ; Ebenbichler, Christoph F ; Baum, Seth J ; Stroes, Erik S.G ; Ali, Shazia ; Khilla, Nagwa ; Hamlin, Robert ; Pordy, Robert ; Dong, Yuping ; Son, Vladimir ; Gaudet, Daniel</creator><creatorcontrib>Rosenson, Robert S ; Burgess, Lesley J ; Ebenbichler, Christoph F ; Baum, Seth J ; Stroes, Erik S.G ; Ali, Shazia ; Khilla, Nagwa ; Hamlin, Robert ; Pordy, Robert ; Dong, Yuping ; Son, Vladimir ; Gaudet, Daniel</creatorcontrib><description>Angiopoietin-like 3 is an inhibitor of lipoprotein lipase. Evinacumab is a monoclonal antibody that inhibits angiopoietin-like 3, activating lipoprotein lipase. In patients with hypercholesterolemia that is refractory to statin and PCSK9 inhibitor therapy, the use of evinacumab reduced plasma lipid levels by more than 50% at the maximum dose.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2031049</identifier><identifier>PMID: 33196153</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adult ; Angiopoietin ; Angiopoietin-like Proteins - antagonists & inhibitors ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Anticholesteremic Agents - administration & dosage ; Anticholesteremic Agents - adverse effects ; Anticholesteremic Agents - therapeutic use ; Arteriosclerosis ; Body weight ; Cardiology ; Cardiovascular disease ; Cholesterol ; Cholesterol, LDL - blood ; Coronary vessels ; Double-Blind Method ; Drug Administration Schedule ; Drug Resistance ; Female ; Humans ; Hypercholesterolemia ; Hyperlipoproteinemia Type II - drug therapy ; Infusions, Intravenous ; Injections, Subcutaneous ; Intravenous administration ; Lipids ; Low density lipoprotein ; Male ; Middle Aged ; Monoclonal antibodies ; Mutation ; Statins</subject><ispartof>The New England journal of medicine, 2020-12, Vol.383 (24), p.2307-2319</ispartof><rights>Copyright © 2020 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2020 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-3cbb89937697ded5b4c91a492e6c21f1c73b17b9874611f8b00bcec671a853bf3</citedby><cites>FETCH-LOGICAL-c390t-3cbb89937697ded5b4c91a492e6c21f1c73b17b9874611f8b00bcec671a853bf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2031049$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2468693508?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2757,2758,26101,27922,27923,52380,54062,64383,64387,72239</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33196153$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rosenson, Robert S</creatorcontrib><creatorcontrib>Burgess, Lesley J</creatorcontrib><creatorcontrib>Ebenbichler, Christoph F</creatorcontrib><creatorcontrib>Baum, Seth J</creatorcontrib><creatorcontrib>Stroes, Erik S.G</creatorcontrib><creatorcontrib>Ali, Shazia</creatorcontrib><creatorcontrib>Khilla, Nagwa</creatorcontrib><creatorcontrib>Hamlin, Robert</creatorcontrib><creatorcontrib>Pordy, Robert</creatorcontrib><creatorcontrib>Dong, Yuping</creatorcontrib><creatorcontrib>Son, Vladimir</creatorcontrib><creatorcontrib>Gaudet, Daniel</creatorcontrib><title>Evinacumab in Patients with Refractory Hypercholesterolemia</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Angiopoietin-like 3 is an inhibitor of lipoprotein lipase. Evinacumab is a monoclonal antibody that inhibits angiopoietin-like 3, activating lipoprotein lipase. In patients with hypercholesterolemia that is refractory to statin and PCSK9 inhibitor therapy, the use of evinacumab reduced plasma lipid levels by more than 50% at the maximum dose.</description><subject>Adult</subject><subject>Angiopoietin</subject><subject>Angiopoietin-like Proteins - antagonists & inhibitors</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Anticholesteremic Agents - administration & dosage</subject><subject>Anticholesteremic Agents - adverse effects</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Arteriosclerosis</subject><subject>Body weight</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Cholesterol</subject><subject>Cholesterol, LDL - blood</subject><subject>Coronary vessels</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance</subject><subject>Female</subject><subject>Humans</subject><subject>Hypercholesterolemia</subject><subject>Hyperlipoproteinemia Type II - drug therapy</subject><subject>Infusions, Intravenous</subject><subject>Injections, Subcutaneous</subject><subject>Intravenous administration</subject><subject>Lipids</subject><subject>Low density lipoprotein</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Statins</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10E1LAzEQBuAgiq3Vo1dZEI-rmU02H3iSUq1SPxA9hyTN0i3Nbk12lf57I1XBg3OZy8M7w4vQMeBzwCW7eJjc3be6wAQwlTtoCCUhOaWY7aIhxoXIKZdkgA5iXOI0QOU-GhACkiU5RJeT97rRtvfaZHWTPemudk0Xs4-6W2TPrgradm3YZNPN2gW7aFcudi6k5Wt9iPYqvYru6HuP0Ov15GU8zWePN7fjq1luicRdTqwxQkrCmeRzNy8NtRI0lYVjtoAKLCcGuJGCUwZQCYOxsc4yDlqUxFRkhE63uevQvvXpAbVs-9Ckk6qgTDBJSiySyrfKhjbG4Cq1DrXXYaMAq6-q1J-qkj_5Tu2Nd_Nf_dNNAmdb4H1UjVv6f4I-AdDobu0</recordid><startdate>20201210</startdate><enddate>20201210</enddate><creator>Rosenson, Robert S</creator><creator>Burgess, Lesley J</creator><creator>Ebenbichler, Christoph F</creator><creator>Baum, Seth J</creator><creator>Stroes, Erik S.G</creator><creator>Ali, Shazia</creator><creator>Khilla, Nagwa</creator><creator>Hamlin, Robert</creator><creator>Pordy, Robert</creator><creator>Dong, Yuping</creator><creator>Son, Vladimir</creator><creator>Gaudet, Daniel</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20201210</creationdate><title>Evinacumab in Patients with Refractory Hypercholesterolemia</title><author>Rosenson, Robert S ; Burgess, Lesley J ; Ebenbichler, Christoph F ; Baum, Seth J ; Stroes, Erik S.G ; Ali, Shazia ; Khilla, Nagwa ; Hamlin, Robert ; Pordy, Robert ; Dong, Yuping ; Son, Vladimir ; Gaudet, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-3cbb89937697ded5b4c91a492e6c21f1c73b17b9874611f8b00bcec671a853bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Angiopoietin</topic><topic>Angiopoietin-like Proteins - antagonists & inhibitors</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Anticholesteremic Agents - administration & dosage</topic><topic>Anticholesteremic Agents - adverse effects</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Arteriosclerosis</topic><topic>Body weight</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Cholesterol</topic><topic>Cholesterol, LDL - blood</topic><topic>Coronary vessels</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance</topic><topic>Female</topic><topic>Humans</topic><topic>Hypercholesterolemia</topic><topic>Hyperlipoproteinemia Type II - drug therapy</topic><topic>Infusions, Intravenous</topic><topic>Injections, Subcutaneous</topic><topic>Intravenous administration</topic><topic>Lipids</topic><topic>Low density lipoprotein</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Statins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosenson, Robert S</creatorcontrib><creatorcontrib>Burgess, Lesley J</creatorcontrib><creatorcontrib>Ebenbichler, Christoph F</creatorcontrib><creatorcontrib>Baum, Seth J</creatorcontrib><creatorcontrib>Stroes, Erik S.G</creatorcontrib><creatorcontrib>Ali, Shazia</creatorcontrib><creatorcontrib>Khilla, Nagwa</creatorcontrib><creatorcontrib>Hamlin, Robert</creatorcontrib><creatorcontrib>Pordy, Robert</creatorcontrib><creatorcontrib>Dong, Yuping</creatorcontrib><creatorcontrib>Son, Vladimir</creatorcontrib><creatorcontrib>Gaudet, Daniel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosenson, Robert S</au><au>Burgess, Lesley J</au><au>Ebenbichler, Christoph F</au><au>Baum, Seth J</au><au>Stroes, Erik S.G</au><au>Ali, Shazia</au><au>Khilla, Nagwa</au><au>Hamlin, Robert</au><au>Pordy, Robert</au><au>Dong, Yuping</au><au>Son, Vladimir</au><au>Gaudet, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evinacumab in Patients with Refractory Hypercholesterolemia</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2020-12-10</date><risdate>2020</risdate><volume>383</volume><issue>24</issue><spage>2307</spage><epage>2319</epage><pages>2307-2319</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Angiopoietin-like 3 is an inhibitor of lipoprotein lipase. Evinacumab is a monoclonal antibody that inhibits angiopoietin-like 3, activating lipoprotein lipase. In patients with hypercholesterolemia that is refractory to statin and PCSK9 inhibitor therapy, the use of evinacumab reduced plasma lipid levels by more than 50% at the maximum dose.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>33196153</pmid><doi>10.1056/NEJMoa2031049</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2020-12, Vol.383 (24), p.2307-2319 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_2468693508 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Adult Angiopoietin Angiopoietin-like Proteins - antagonists & inhibitors Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Anticholesteremic Agents - administration & dosage Anticholesteremic Agents - adverse effects Anticholesteremic Agents - therapeutic use Arteriosclerosis Body weight Cardiology Cardiovascular disease Cholesterol Cholesterol, LDL - blood Coronary vessels Double-Blind Method Drug Administration Schedule Drug Resistance Female Humans Hypercholesterolemia Hyperlipoproteinemia Type II - drug therapy Infusions, Intravenous Injections, Subcutaneous Intravenous administration Lipids Low density lipoprotein Male Middle Aged Monoclonal antibodies Mutation Statins |
| title | Evinacumab in Patients with Refractory Hypercholesterolemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T22%3A02%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evinacumab%20in%20Patients%20with%20Refractory%20Hypercholesterolemia&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Rosenson,%20Robert%20S&rft.date=2020-12-10&rft.volume=383&rft.issue=24&rft.spage=2307&rft.epage=2319&rft.pages=2307-2319&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2031049&rft_dat=%3Cproquest_cross%3E2468693508%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2468693508&rft_id=info:pmid/33196153&rfr_iscdi=true |